Women with breast cancer who received capecitabine after adjuvant epirubicin had better quality of life (QOL) compared with those who received CMF after adjuvant therapy.
Breast cancer survivors who received taxane-based chemotherapy for their disease are at increased risk for falls due to CIPN and treatment-associated effects on balance and gait.
Data from the National Cancer Database are indicating that wait times from cancer diagnosis to initial treatment were substantially longer over a 5-year period.
Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Ovarian function recovery (OFR) in women with chemotherapy-induced ovarian function failure decreases residual 5-year disease-free and overall survival.
Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.
Lanreotide decreased the proportion of days patients had flushing and diarrhea compared with placebo, even in patients previously responsive to rescue therapy with octreotide.
Patients with adherence problems were more likely to take their pills compared with those who received standard care.
Combining extracorporeal shock wave (ESW) technique with nanoparticle delivery improves treatment of difficult-to-treat solid tumors, such as anaplastic thyroid cancer.
Flushing the bladder with a chemotherapeutic agent after tumor resection significantly reduced recurrence rates of bladder cancer.
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
Daily CHG bathing can safely reduce CLABSIs in oncology patients with central lines, with small variations in efficacy of the practice due to differences in patient population, work processes, and team engagement.
Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.
Temozolomide, an antimitotic chemotherapy used to treat brain cancer, demonstrated the potential to increase depression in a mouse model.
Standardized tool improved efficiency and thoroughness of patient assessment and documentation of neurotoxicity caused by high-dose cytarabine.
A literature review noted improvements in quality of life after patients were coached and educated following radiotherapy for HPV-associated oropharyngeal cancers.
A new CSTD significantly reduced surface contamination during a simulated antineoplastic hazardous drug administration when compared to baseline.
Prior assessment of patients and review of infusion orders by an interprofessional ACE team can significantly reduce patient wait times, prevent same-day inefficiencies, and reduce wasted chemotherapy doses.
Long-acting NK-1 receptor antagonist rolapitant demonstrates significant efficacy in managing CINV in patients receiving HEC or MEC for cancer.
Women with triple-negative or HER2-positive breast cancer who achieve a pathologic complete response from neoadjuvant chemotherapy may be able to avoid follow-up breast or lymph node surgery.
Online Module Seeks to Educate Nurses on the Identification and Management of Hypersensitivity Reactions to ChemotherapyMay 01, 2017
Hypersensitivity reactions in patients receiving chemotherapy are not common, but their serious nature requires that oncology nurses be able to manage them when they occur.
Short-term fasting may alleviate toxic effects caused by high blood glucose levels associated with common cancer drugs.
Regular infusions of high doses of vitamin C safely increased cancer cell sensitivity to treatment in patients with brain and lung cancers.
Exercise helps patients with gastrointestinal cancer undergoing chemotherapy cope with their disease and treatment.
A study using a mouse model to investigate the effect of adding everolimus to cyclophosphamide to slow tumor growth found the drug also preserves fertility.
In patients with soft tissue sarcoma pretreated with doxorubicin, treatment with regorafenib significantly reduced the risk of progression symptoms or toxicity.
Use of chemotherapy or vaginal brachytherapy (VBT) may improve survival among patients with early-stage uterine papillary serous carcinoma.
Nicotinamide riboside, a type of B3 vitamin, was shown to prevent chemotherapy-induced peripheral neuropathy in an animal-model study.
Quantity and quality of skeletal muscle is a more accurate measure for determining dose and of potential treatment-related toxicity in patients receiving chemotherapy for early-stage breast cancer.
Supplemental ginger before and during treatment raises antioxidant levels in patients undergoing chemotherapy.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|